Evotec Announced Expansion of Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb (NYSE: BMY) with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases incl
Evotec Announced Receipt of €7.5M Grant for Development of COVID-19 Therapeutic
Evotec SE (Frankfurt Stock Exchange:EVT) MDAX/TecDAX, ISIN: DE0005664809 (NASDAQ: EVO) announced today that the Company has been selected by the German Federal Ministry of Education and Research ("BMBF") to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID-19.
Cowen & Co. Initiates Coverage On Evotec with Outperform Rating
Cowen & Co. analyst Max Masucci initiates coverage on Evotec (NASDAQ:EVO) with a Outperform rating.
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.